Evidence map›Paper›PMID 42930780›Full record

ReviewJournal of personalized medicine2026

Semaglutide in Atrial Arrhythmias: State of the Art and Future Perspectives.

Enrico Maggio, Sara Trivigno, Marco Valerio Mariani, Agostino Piro, Nicola Pierucci, Antonio Vernile, Sara Vinciullo, Marta Palombi, Carmine Dario Vizza, Carlo Lavalle

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of personalized medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Enrico MaggioDepartment of Medical and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00159 Rome, Italy.ORCID 0000-0002-9758-8482
Sara TrivignoDepartment of Medical and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00159 Rome, Italy.ORCID 0000-0002-0968-7553
Marco Valerio MarianiDepartment of Medical and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00159 Rome, Italy.ORCID 0000-0002-9480-1209
Agostino PiroDepartment of Medical and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00159 Rome, Italy.
Nicola PierucciDepartment of Medical and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00159 Rome, Italy.
Antonio VernileDepartment of Medical and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00159 Rome, Italy.
Sara VinciulloDepartment of Medical and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00159 Rome, Italy.
Marta PalombiDepartment of Medical and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00159 Rome, Italy.ORCID 0009-0005-5092-3115
Carmine Dario VizzaDepartment of Medical and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00159 Rome, Italy.ORCID 0000-0002-3540-4983
Carlo LavalleDepartment of Medical and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00159 Rome, Italy.ORCID 0000-0002-0794-4296

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiac arrhythmias, particularly atrial fibrillation (AF), represent a major cause of morbidity and mortality worldwide, especially in individuals with type 2 diabetes mellitus (T2D), obesity, and cardiovascular disease. Traditional antiarrhythmic drugs (AADs) remain the cornerstone of rhythm control, but their efficacy is limited and often accompanied by adverse effects. A multidimensional approach that includes upstream therapy-targeting metabolic, structural and inflammatory substrates-has therefore emerged as a critical strategy in arrhythmia prevention and management. Among novel therapeutic agents, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), particularly semaglutide, are gaining attention for their potential antiarrhythmic properties beyond glycaemic control. This review discusses multidimensional arrhythmia management, current indications for semaglutide, and future perspectives on its role as a potential upstream antiarrhythmic therapy.

Indexed as

atrial arrhythmiasatrial fibrillationGLP-1 receptor agonistsnarrative reviewobesitysemaglutide

Identifiers

PMID42930780
PMCPMC13706129

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.